What is the optimal duration of immune checkpoint inhibitors in malignant tumors?

Overview of attention for article published in Frontiers in immunology, September 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 2 news outlets

twitter: 8 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 14 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

The Lasting Benefit of Immune Checkpoint Inhibitors

Cancer Today, 20 Dec 2023

Forward Look Study suggests people with advanced lung cancer who have a sustained response to immunotherapy can safely stop…

免疫治疗持续多久？2年后停药或继续？

CN-Healthcare, 25 Sep 2023

随着各项临床研究的开展，新鲜数据的出炉，相信我们癌症治疗的策略会有更深入的了解，促进癌症治疗模式的转变，让免疫治疗更具创新性、个体性。由国际肺癌研究协会（IASLC）举办的2023世界肺癌大会（WCLC）已于9月12日在新加坡落下帷幕。作为全球规模最大的肿…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.